Peringatan Keamanan

Reported oral dose range for moderate toxicity or possibly lethal toxicity in humans is 0.5-5 g/kg L2733. Nephropathy, encephalopathy, osteoarthropathy, gingivitis, stomatitis and colitis have been attributed to bismuth toxicity in humans A33021.

Bismuth subnitrate

DB13209

small molecule approved

Deskripsi

Bismuth subnitrate, also referred to as bismuth oxynitrate or bismuthyl nitrate, is a highly water-soluble crystalline compound that has been used as a treatment for duodenal ulcers and anti-diarrheic agent A33012. The use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA.

Struktur Molekul 2D

Berat 1461.98
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The distribution half-life of bismuth is approximately 1 to 4 hours, and the elimination half-life is 5 to 11 days [L2733].
Volume Distribusi Bismuth has been shown to accumulate preferentially in the kidneys [A33012].
Klirens (Clearance) No pharmacokinetic data available.

Absorpsi

Bismuth subnitrate may undergo minimal gastrointestinal absorption which may be potentiated with concomitant administration of sulfhydryl compounds L2733 when dissolved in citrate buffer solution A33012. Approximately 0.2% of orally administered bismuth is absorbed systematically from the gastrointestinal tract with the peak plasma concentration typically occurring within 1 hour L2733.

Metabolisme

No pharmacokinetic data available.

Rute Eliminasi

Bismuth may undergo both urinary and faecal excretion, however the exact proportion contributed by each route is still unknown A33021.

Interaksi Obat

272 Data
Atazanavir Bismuth subnitrate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bosutinib Bismuth subnitrate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cefditoren The serum concentration of Cefditoren can be decreased when it is combined with Bismuth subnitrate.
Dabigatran etexilate Bismuth subnitrate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dabrafenib Bismuth subnitrate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dasatinib Bismuth subnitrate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Delavirdine Bismuth subnitrate can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Erlotinib Bismuth subnitrate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gefitinib Bismuth subnitrate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Itraconazole Bismuth subnitrate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ledipasvir Bismuth subnitrate can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylphenidate Bismuth subnitrate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Pazopanib Bismuth subnitrate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Riociguat Bismuth subnitrate can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy.
Levothyroxine Bismuth subnitrate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tolevamer The risk or severity of adverse effects can be increased when Tolevamer is combined with Bismuth subnitrate.
Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Bismuth subnitrate.
Captopril Bismuth subnitrate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cefpodoxime The serum concentration of Cefpodoxime can be decreased when it is combined with Bismuth subnitrate.
Cefuroxime The serum concentration of Cefuroxime can be decreased when it is combined with Bismuth subnitrate.
Chloroquine Bismuth subnitrate can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Elvitegravir Bismuth subnitrate can cause a decrease in the absorption of Elvitegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Hyoscyamine Bismuth subnitrate can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rifampin Bismuth subnitrate can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mecamylamine Bismuth subnitrate may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
Memantine Bismuth subnitrate may decrease the excretion rate of Memantine which could result in a higher serum level.
Quinidine Bismuth subnitrate may decrease the excretion rate of Quinidine which could result in a higher serum level.
Sulpiride The therapeutic efficacy of Sulpiride can be increased when used in combination with Bismuth subnitrate.
Allopurinol The therapeutic efficacy of Allopurinol can be decreased when used in combination with Bismuth subnitrate.
Raltegravir The serum concentration of Raltegravir can be decreased when it is combined with Bismuth subnitrate.
Mesalazine Bismuth subnitrate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolate mofetil Bismuth subnitrate can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolic acid Bismuth subnitrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cysteamine The bioavailability of Cysteamine can be decreased when combined with Bismuth subnitrate.
Ketoconazole Bismuth subnitrate can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bismuth subsalicylate Bismuth subsalicylate may increase the neurotoxic activities of Bismuth subnitrate.
Bismuth subcitrate potassium Bismuth subcitrate potassium may increase the neurotoxic activities of Bismuth subnitrate.
Bismuth subgallate Bismuth subnitrate may increase the neurotoxic activities of Bismuth subgallate.
Valproate bismuth Bismuth subnitrate may increase the neurotoxic activities of Valproate bismuth.
Thiethylperazine Bismuth subnitrate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Promazine Bismuth subnitrate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Prochlorperazine Bismuth subnitrate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Chlorpromazine Bismuth subnitrate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Triflupromazine Bismuth subnitrate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fluphenazine Bismuth subnitrate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Thioridazine Bismuth subnitrate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Moricizine Bismuth subnitrate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Trifluoperazine Bismuth subnitrate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Perphenazine Bismuth subnitrate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mesoridazine Bismuth subnitrate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetophenazine Bismuth subnitrate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Promethazine Bismuth subnitrate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alimemazine Bismuth subnitrate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methotrimeprazine Bismuth subnitrate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Periciazine Bismuth subnitrate can cause a decrease in the absorption of Periciazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acepromazine Bismuth subnitrate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aceprometazine Bismuth subnitrate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pipotiazine Bismuth subnitrate can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Thioproperazine Bismuth subnitrate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
BL-1020 Bismuth subnitrate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cyamemazine Bismuth subnitrate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylene blue Bismuth subnitrate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.
Propiopromazine Bismuth subnitrate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Perazine Bismuth subnitrate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Butaperazine Bismuth subnitrate can cause a decrease in the absorption of Butaperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Chlorproethazine Bismuth subnitrate can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Thiazinam Bismuth subnitrate can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dixyrazine Bismuth subnitrate can cause a decrease in the absorption of Dixyrazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Perphenazine enanthate Bismuth subnitrate can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methenamine The therapeutic efficacy of Methenamine can be decreased when used in combination with Bismuth subnitrate.
Doxycycline Bismuth subnitrate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lymecycline Bismuth subnitrate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Clomocycline Bismuth subnitrate can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxytetracycline Bismuth subnitrate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Demeclocycline Bismuth subnitrate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tetracycline Bismuth subnitrate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Metacycline Bismuth subnitrate can cause a decrease in the absorption of Metacycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Minocycline Bismuth subnitrate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sarecycline Bismuth subnitrate can cause a decrease in the absorption of Sarecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Omadacycline Bismuth subnitrate can cause a decrease in the absorption of Omadacycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Penimepicycline Bismuth subnitrate can cause a decrease in the absorption of Penimepicycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Triethylenetetramine Bismuth subnitrate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rosuvastatin Bismuth subnitrate can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pamidronic acid The serum concentration of Pamidronic acid can be decreased when it is combined with Bismuth subnitrate.
Zoledronic acid The serum concentration of Zoledronic acid can be decreased when it is combined with Bismuth subnitrate.
Alendronic acid The serum concentration of Alendronic acid can be decreased when it is combined with Bismuth subnitrate.
Ibandronate The serum concentration of Ibandronate can be decreased when it is combined with Bismuth subnitrate.
Clodronic acid The serum concentration of Clodronic acid can be decreased when it is combined with Bismuth subnitrate.
Risedronic acid The serum concentration of Risedronic acid can be decreased when it is combined with Bismuth subnitrate.
Etidronic acid The serum concentration of Etidronic acid can be decreased when it is combined with Bismuth subnitrate.
Tiludronic acid The serum concentration of Tiludronic acid can be decreased when it is combined with Bismuth subnitrate.
Incadronic acid The serum concentration of Incadronic acid can be decreased when it is combined with Bismuth subnitrate.
Amphetamine The serum concentration of Amphetamine can be increased when it is combined with Bismuth subnitrate.
Phentermine The serum concentration of Phentermine can be increased when it is combined with Bismuth subnitrate.
Pseudoephedrine The serum concentration of Pseudoephedrine can be increased when it is combined with Bismuth subnitrate.
Benzphetamine The serum concentration of Benzphetamine can be increased when it is combined with Bismuth subnitrate.
Diethylpropion The serum concentration of Diethylpropion can be increased when it is combined with Bismuth subnitrate.
Lisdexamfetamine The serum concentration of Lisdexamfetamine can be increased when it is combined with Bismuth subnitrate.
Mephentermine The serum concentration of Mephentermine can be increased when it is combined with Bismuth subnitrate.
MMDA The serum concentration of MMDA can be increased when it is combined with Bismuth subnitrate.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 14530870
    Kondo Y, Himeno S, Satoh M, Naganuma A, Nishimura T, Imura N: Citrate enhances the protective effect of orally administered bismuth subnitrate against the nephrotoxicity of cis-diamminedichloroplatinum. Cancer Chemother Pharmacol. 2004 Jan;53(1):33-8. doi: 10.1007/s00280-003-0706-9. Epub 2003 Oct 7.
  • PMID: 2129809
    Pugh S, Lewin MR: Mechanism of action of Roter (bismuth subnitrate) in patients with duodenal ulcer disease and healthy volunteers. J Gastroenterol Hepatol. 1990 Jul-Aug;5(4):382-6.
  • PMID: 7733075
    Forne M, Viver JM, Espinos JC, Coll I, Tresserra F, Garau J: Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. Am J Gastroenterol. 1995 May;90(5):718-21.
  • PMID: 2682129
    Slikkerveer A, de Wolff FA: Pharmacokinetics and toxicity of bismuth compounds. Med Toxicol Adverse Drug Exp. 1989 Sep-Oct;4(5):303-23.

Contoh Produk & Brand

Produk: 1 • International brands: 0
Produk
  • Hemorro-dol Sup
    Suppository • - • Rectal • Canada • OTC • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul